Boiron (BOIR.F) Stock Overview

Manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. More details

BOIR.F fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	3/6
Past Performance	0/6
Financial Health	5/6
Dividends	2/6

Rewards

Trading at 57.2% below our estimate of its fair value

Earnings are forecast to grow 23.49% per year

Risk Analysis

Shares are highly illiquid

Large one-off items impacting financial results

Dividend of 3.95% is not well covered by earnings

BOIR.F Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Boiron SA Competitors

Price History & Performance

Summary of share price highs, lows and changes for Boiron
Historical stock prices
Current Share Price	€30.00
52 Week High	€32.28
52 Week Low	€24.00
Beta	0.34
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	-27.54%
Change since IPO	30.15%

Recent updates

Shareholder Returns

	BOIR.F	US Pharmaceuticals	US Market
7D	0%	1.9%	-0.3%
1Y	n/a	29.7%	13.0%

Return vs Industry: Insufficient data to determine how BOIR.F performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how BOIR.F performed against the US Market.

Price Volatility

Is BOIR.F's price volatile compared to industry and market?
BOIR.F volatility
BOIR.F Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	9.8%
Market Average Movement	6.5%
10% most volatile stocks in US Market	16.4%
10% least volatile stocks in US Market	3.0%

Stable Share Price: BOIR.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine BOIR.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1932	2,736	Pascal Houdayer	www.boiron.fr

Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines and homeopathic specialties; and other healthcare products, including medical devices, invitro diagnostics, herbal medicine, food supplements, cosmetics and CBD-based products. It also provides homeopathic specialties comprising Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; Sédatif PC to treat anxiety and emotional, and minor sleep disorders; Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; Homéovox for vocal disorders; Homéoplasmine for treating irritated skin and redness; Varésol to treat symptoms of chickenpox; and Arnicare Arthritis for use in the treatment of benign trauma pain.

Boiron SA Fundamentals Summary

How do Boiron's earnings and revenue compare to its market cap?
BOIR.F fundamental statistics
Market cap	US$616.82m
Earnings (TTM)	US$22.63m
Revenue (TTM)	US$590.00m

27.3x

P/E Ratio

1.0x

P/S Ratio

Is BOIR.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BOIR.F income statement (TTM)
Revenue	€504.86m
Cost of Revenue	€132.74m
Gross Profit	€372.12m
Other Expenses	€352.76m
Earnings	€19.37m

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	1.12
Gross Margin	73.71%
Net Profit Margin	3.84%
Debt/Equity Ratio	2.1%

How did BOIR.F perform over the long term?

See historical performance and comparison

Dividends

3.9%

Current Dividend Yield

108%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/01/22 05:53
End of Day Share Price	2025/11/13 00:00
Earnings	2025/06/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Boiron SA is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Guillaume Cuvillier	Gilbert Dupont
Stephanie Lefebvre	Gilbert Dupont
Christophe-Raphael Ganet	ODDO BHF Corporate & Markets

Boiron SAOTCPK:BOIR.F Stock Report